Heron Therapeutics, Inc. (HRTX)
Largest Insider Buys in Sector
HRTX Stock Price History Chart
HRTX Stock Performance
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Insider Activity of Heron Therapeutics, Inc.
Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $3.69M and sold $0 worth of Heron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $4.43M and sold $395,403 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Morgan Adam (director) — $6.81M. Forbes William P (EVP, Chief Development Officer) — $148,490. Collard Craig A (Chief Executive Officer) — $137,970.
The last purchase of 25,000 shares for transaction amount of $27,250 was made by Forbes William P (EVP, Chief Development Officer) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Heron Therapeutics, Inc.
| 2023-11-17 | Forbes William P | EVP, Chief Development Officer | 25,000 0.0179% | $1.09 | $27,250 | +140.74% | ||
| 2023-11-16 | Collard Craig A | Chief Executive Officer | 150,000 0.1065% | $0.92 | $137,970 | +179.27% | ||
| 2023-11-16 | Duarte Ira | EVP, Chief Financial Officer | 85,000 0.0584% | $0.89 | $75,599 | +179.27% | ||
| 2023-11-16 | Forbes William P | EVP, Chief Development Officer | 50,000 0.0363% | $0.94 | $46,995 | +179.27% | ||
| 2023-07-21 | Morgan Adam | director | 2.49M 2.0703% | $1.37 | $3.41M | +50.92% | ||
| 2022-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 1,504 0.0015% | $4.76 | $7,154 | -38.95% | |
| 2021-12-21 | Sale | Christian Waage | director | 300 0.0003% | $9.73 | $2,920 | -56.73% | |
| 2021-12-21 | Sale | Johnson Craig A | director | 250 0.0002% | $9.73 | $2,432 | -56.73% | |
| 2021-09-21 | Sale | Christian Waage | director | 600 0.0006% | $12.31 | $7,384 | -54.08% | |
| 2021-09-21 | Sale | Johnson Craig A | director | 500 0.0005% | $12.30 | $6,148 | -54.08% | |
| 2021-06-21 | Sale | Christian Waage | director | 600 0.0006% | $15.20 | $9,118 | -40.10% | |
| 2021-06-21 | Sale | Johnson Craig A | director | 500 0.0005% | $15.20 | $7,601 | -40.10% | |
| 2021-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 3,058 0.0032% | $17.66 | $54,017 | -39.34% | |
| 2021-04-15 | Sale | Christian Waage | director | 600 0.0006% | $17.51 | $10,508 | -38.97% | |
| 2021-04-06 | Sale | Johnson Craig A | director | 500 0.0005% | $17.22 | $8,610 | -33.90% | |
| 2021-01-14 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 1,654 0.0018% | $18.09 | $29,920 | -29.12% | |
| 2021-01-08 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 7,142 0.0039% | $9.83 | $70,219 | -32.19% | |
| 2020-12-22 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 20,000 0.0176% | $16.50 | $330,000 | -32.95% | |
| 2020-05-01 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 2,316 0.0013% | $6.98 | $16,176 | +25.16% | |
| 2019-11-29 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 48,000 0.0274% | $13.00 | $624,000 | -35.68% |
Insider Historical Profitability
| Morgan Adam | director | 6986744 4.6556% | $3.33 | 1 | 0 | |
| Collard Craig A | Chief Executive Officer | 186496 0.1243% | $3.33 | 1 | 0 | |
| Duarte Ira | EVP, Chief Financial Officer | 85000 0.0566% | $3.33 | 1 | 0 | |
| Forbes William P | EVP, Chief Development Officer | 79000 0.0526% | $3.33 | 2 | 0 | |
| TANG KEVIN C | director | 5799810 3.8647% | $3.33 | 19 | 1 | +4.62% |
| Savitr Capital, LLC | Exiting 10% holder | 1712366 1.141% | $3.33 | 0 | 26 | |
| RIEPENHAUSEN PETER | director | 179332 0.1195% | $3.33 | 2 | 0 | |
| Quart Barry D | Chief Executive Officer | 94652 0.0631% | $3.33 | 3 | 4 | <0.0001% |
| SPCH, LLC | Exiting 10% holder | 79238 0.0528% | $3.33 | 1 | 11 | |
| TURNBULL GREG | President & CEO | 56159 0.0374% | $3.33 | 3 | 0 | <0.0001% |
| GODDARD PAUL | director | 45000 0.03% | $3.33 | 1 | 0 | |
| POYHONEN JOHN | EVP, Chief Commercial Officer | 18143 0.0121% | $3.33 | 3 | 0 | +2.43% |
| MANHARD KIMBERLY | EVP, Drug Development | 10872 0.0072% | $3.33 | 0 | 14 | |
| Christian Waage | director | 3200 0.0021% | $3.33 | 1 | 4 | +1.43% |
| Johnson Craig A | director | 2840 0.0019% | $3.33 | 0 | 4 | |
| Rosen Robert | President | 2640 0.0018% | $3.33 | 0 | 6 | |
| PRENTKI RONALD J | President & CEO | 1860 0.0012% | $3.33 | 2 | 0 | <0.0001% |
| HOFFMAN ROBERT | CFO & SVP, Finance | 1280 0.0009% | $3.33 | 0 | 1 | |
| Marshall Paul | SVP, Technical Operations | 0 0% | $3.33 | 0 | 1 | |
| ROSENBLATT TOBY | director | 0 0% | $3.33 | 0 | 1 | |
| Szekeres David Leslie | EVP, Chief Operating Officer | 0 0% | $3.33 | 0 | 2 |
Institutional Investor Ownership
| Helm Capital Management LLC | $74M | 17.73 | 26.71M | 0% | +$0 | 2.19 | |
| OrbiMed | $28.01M | 6.71 | 10.11M | +70.56% | +$11.59M | 0.57 | |
| The Vanguard Group | $22.48M | 5.39 | 8.11M | -2.69% | -$621,022.91 | <0.0001 | |
| BlackRock | $20.18M | 4.84 | 7.29M | +1.73% | +$342,582.51 | <0.0001 | |
| Velan Capital | $19.35M | 4.64 | 6.99M | 0% | +$0 | 10.53 | |
| Franklin Templeton Investments | $17.66M | 4.23 | 6.37M | -0.47% | -$83,684.47 | 0.01 | |
| Tejara Capital Ltd | $12.22M | 2.93 | 4.41M | -16.37% | -$2.39M | 4.14 | |
| Palisade Capital Management | $10.34M | 2.48 | 3.73M | +2.36% | +$238,602.27 | 0.31 | |
| Millennium Management LLC | $8.77M | 2.1 | 3.17M | +156.01% | +$5.35M | 0.01 | |
| Adage Capital Partners Gp L L C | $8.06M | 1.93 | 2.91M | 0% | +$0 | 0.02 | |
| Geode Capital Management | $7.75M | 1.86 | 2.8M | +6.53% | +$474,984.71 | <0.01 | |
| Clearline Capital LP | $7.69M | 1.84 | 2.78M | -54.25% | -$9.12M | 0.76 | |
| D. E. Shaw & Co. | $7.47M | 1.79 | 2.7M | +108.76% | +$3.89M | 0.01 | |
| State Street | $6.76M | 1.62 | 2.44M | -1.65% | -$113,500.75 | <0.0001 | |
| Renaissance Technologies | $6.67M | 1.6 | 2.41M | +27.78% | +$1.45M | 0.01 | |
| JW Asset Management LLC | $6.35M | 1.52 | 2.29M | 0% | +$0 | 2.32 | |
| Orchard Capital Managment Llc | $6.29M | 1.51 | 2.27M | +1.27% | +$78,825.89 | 1.85 | |
| Tang Capital Management, LLC | $5.12M | 1.23 | 1.85M | 0% | +$0 | 0.02 | |
| Monaco Asset Management Sam | $5.02M | 1.2 | 1.81M | -18.56% | -$1.14M | 2.31 | |
| Congress Park Capital Llc | $4.56M | 1.09 | 1.64M | -8.55% | -$426,206.10 | 2.02 | |
| Goldman Sachs | $3.88M | 0.93 | 1.4M | +42.22% | +$1.15M | <0.01 | |
| Nuveen | $3.03M | 0.73 | 1.09M | +1,093.09% | +$2.78M | <0.01 | |
| New York State Common Retirement Fund | $3.03M | 0.73 | 1.09M | <0.01% | -$132.97 | <0.01 | |
| Charles Schwab | $3.02M | 0.72 | 1.09M | +9.42% | +$260,205.47 | <0.01 | |
| Northern Trust | $2.66M | 0.64 | 959,550 | -2.89% | -$79,058.59 | <0.0001 | |
| Citadel Advisors LLC | $1.59M | 0.38 | 573,437 | +50.2% | +$530,892.50 | <0.01 | |
| Qube Research & Technologies | $1.56M | 0.37 | 561,984 | New | +$1.56M | <0.01 | |
| Marshall Wace | $1.37M | 0.33 | 494,354 | New | +$1.37M | <0.01 | |
| Los Angeles Capital Management LLC | $1.37M | 0.33 | 493,264 | -4.11% | -$58,483.00 | 0.01 | |
| Highland Capital Management Fund Advisors L P | $1.32M | 0.32 | 475,750 | 0% | +$0 | 0.3 | |
| Zacks Investment Management | $1.21M | 0.29 | 436,473 | +40.15% | +$346,372.11 | 0.01 | |
| Wellington Management Company | $1.16M | 0.28 | 417,985 | New | +$1.16M | <0.0001 | |
| Panagora | $1.04M | 0.25 | 375,426 | +169.87% | +$654,587.00 | 0.01 | |
| BNY Mellon | $929,493.00 | 0.22 | 335,557 | -17.02% | -$190,612.03 | <0.0001 | |
| Fidelity Investments | $886,240.00 | 0.21 | 319,943 | +0.09% | +$831.00 | <0.0001 | |
| Cm Management Llc | $831,000.00 | 0.2 | 300,000 | -7.69% | -$69,250.00 | 0.04 | |
| Richmond Brothers, Inc. | $821,876.00 | 0.2 | 296,706 | 0% | +$0 | 1.53 | |
| KBC Group | $801,000.00 | 0.19 | 289,269 | 0% | +$0 | <0.01 | |
| Gsa Capital Partners Llp | $775,000.00 | 0.19 | 279,699 | -17.6% | -$165,554.67 | 0.06 | |
| Eam Investors | $760,393.00 | 0.18 | 274,510 | New | +$760,393.00 | 0.12 | |
| Jane Street Capital | $743,642.00 | 0.18 | 268,463 | +61.15% | +$282,171.40 | <0.01 | |
| Bank of America | $651,066.00 | 0.16 | 235,042 | +26.04% | +$134,522.21 | <0.0001 | |
| Xtx Topco Ltd | $578,340.00 | 0.14 | 208,787 | +100.23% | +$289,501.02 | 0.03 | |
| Morgan Stanley | $551,229.00 | 0.13 | 198,999 | -56.94% | -$728,925.07 | <0.0001 | |
| Susquehanna International Group | $514,937.00 | 0.12 | 185,898 | +168.54% | +$323,183.92 | <0.01 | |
| D.A. Davidson Companies | $473,670.00 | 0.11 | 171,000 | +468.11% | +$390,293.00 | <0.01 | |
| AllianceBernstein | $457,133.00 | 0.11 | 165,030 | -14.77% | -$79,194.28 | <0.0001 | |
| RhumbLine Advisers | $388,454.00 | 0.09 | 140,242 | +3.27% | +$12,312.13 | <0.0001 | |
| Barclays | $378,000.00 | 0.09 | 136,459 | -23.66% | -$117,159.81 | <0.0001 | |
| Apeiron Ria Llc | $343,480.00 | 0.08 | 124,000 | +49.4% | +$113,570.00 | 0.11 |